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Abstract
Background: Propionic acidaemia (PA) results from deficiency of Propionyl CoA carboxylase, the commonest form
presenting in the neonatal period. Despite best current management, PA is associated with severe neurological
sequelae, in particular movement disorders resulting from basal ganglia infarction, although the pathogenesis
remains poorly understood. The role of liver transplantation remains controversial but may confer some neuro-
protection. The present study utilises quantitative magnetic resonance spectroscopy (MRS) to investigate brain
metabolite alterations in propionic acidaemia during metabolic stability and acute encephalopathic episodes.
Methods: Quantitative MRS was used to evaluate brain metabolites in eight children with neonatal onset
propionic acidaemia, with six elective studies acquired during metabolic stability and five studies during acute
encephalopathic episodes. MRS studies were acquired concurrently with clinically indicated MR imaging studies at
1.5 Tesla. LCModel software was used to provide metabolite quantification. Comparison was made with a dataset
of MRS metabolite concentrations from a cohort of children with normal appearing MR imaging.
Results: MRI findings confirm the vulnerability of basal ganglia to infarction during acute encephalopathy. We
identified statistically significant decreases in basal ganglia glutamate+glutamine and N-Acetylaspartate, and
increase in lactate, during encephalopathic episodes. In white matter lactate was significantly elevated but other
metabolites not significantly altered. Metabolite data from two children who had received liver transplantation
were not significantly different from the comparator group.
Conclusions: The metabolite alterations seen in propionic acidaemia in the basal ganglia during acute
encephalopathy reflect loss of viable neurons, and a switch to anaerobic respiration. The decrease in glutamine +
glutamate supports the hypothesis that they are consumed to replenish a compromised Krebs cycle and that this
is a marker of compromised aerobic respiration within brain tissue. Thus there is a need for improved brain
protective strategies during acute metabolic decompensations. MRS provides a non-invasive tool for which could
be employed to evaluate novel treatments aimed at restoring basal ganglia homeostasis. The results from the liver
transplantation sub-group supports the hypothesis that liver transplantation provides systemic metabolic stability
by providing a hepatic pool of functional propionyl CoA carboxylase, thus preventing further acute
decompensations which are associated with the risk of brain infarction.
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Propionic acidaemia (PA, OMIM #606054) results from
deficiency of the biotin-dependent mitochondrial
enzyme propionyl CoA carboxylase. The commonest
and most severe form of PA presents in the neonatal
period with acute metabolic acidosis, hyperammonaemia
and progressive encephalopathy. Despite optimal man-
agement, later neurologic sequelae are a major cause of
morbidity, and include neurodevelopmental delay, episo-
dic acute encephalopathy, and movement disorders due
to a propensity to basal ganglia infarction [1]. The main-
stays of current treatment are dietary protein restriction,
carnitine supplementation, and aggressive management
of acute metabolic derangements. Some centres utilise
alternative pathway drugs including sodium benzoate to
minimise the consequences of hyperammonaemia.
Orthotopic liver transplantation may prevent neurocog-
nitive decline [2] but its role remains controversial.
The pathogenesis of the neurological insult remains
poorly understood. Neurological damage may occur sec-
ondary to hyperammonaemia; alternatively inhibition of
the mitochondrial Krebs cycle and electron transfer chain
by accumulating metabolites may lead to a “bioenergetic
stroke” [3]. Based on alterations in plasma amino acids
associated with hyperammonaemia it has been hypothe-
sised that the use of dietary supplements including gluta-
mine that can replenish the Krebs cycle (anaplerotic
therapy) may support aerobic cellular energy metabolism
and hence improve clinical outcome [4]. Conflicting
changes in cerebrospinal fluid glutamine concentrations
have been reported in PA [5,6].
Magnetic resonance spectroscopy (MRS) is a non-inva-
sive technique capable of probing in vivo changes in
regional metabolites within the brain, and could be speci-
fically employed to monitor directly alterations in brain
energy metabolites including glutamine, glutamate and
lactate. Previous MRS reports have demonstrated ele-
vated glutamine+glutamate (Glx) in the basal ganglia of
metabolically stable PA patients [6], while lactate has
been detected in periventricular white matter [7].
The present study utilises quantitative MRS to investi-
gate brain metabolite alterations both during metabolic
stability and acute encephalopathic episodes, confirming
the basal ganglia as a particular target and demonstrating
novel insights in to alterations in neurotransmitter meta-
bolites in particular glutamine and glutamate.
Methods
Patients
Eight children (two female) with propionic acidaemia
were studied (median age (range) at first MRS, 36 (7-190)
months) (see table 1). Research Ethics Committee
approval and informed consent were obtained. All were
diagnosed in the neonatal period, four requiring neonatal
haemofiltration due to severe hyperammonaemia and
metabolic acidosis. Two children had received elective
orthotopic liver transplantation during early childhood.
The remaining six children all received regular oral carni-
tine and sodium benzoate, and three received sodium
phenylbutyrate, in additiont od i e t a r yp r o t e i nc o n t r o l
under management of a specialist dietetic team.
Three children had one or more severe acute epi-
sodes with encephalopathy beyond the neonatal period
requiring intensive care support ("severe acute episode”
hereafter). During these episodes all children required
ventilatory support and continuous veno-venous hae-
mofiltration (CVVH), and only one episode was asso-
ciated with significant persistent hyperammonaemia.
During these episodes three children received intrave-
nous sodium benzoate and two received sodium
phenylbutyrate.
Magnetic Resonance Spectroscopy
MRS studies were performed concurrently with clinically
indicated MRI scans at 1.5 Tesla (Siemens Symphony
Magnetom, NUM4 or GE Signa Excite & HDx) facili-
tated by general anaesthesia as needed. Five studies
from three children were acquired during severe acute
episodes requiring intensive care support. Six studies
from six children were acquired with elective outpatient
MRI studies undertaken during metabolic stability and
before any severe acute episode had occurred.
MRS was acquired using point resolved spectroscopy
(PRESS) technique (echo time 30 ms and 135 ms, repeti-
tion time 1500 ms, 128 repetitions) with 2 cm-sided vox-
els located in the left basal ganglia and right parieto-
occipital white matter. Voxels were placed in standard
positions guided by T1 and T2 weighted image sequences
in coronal, sagittal and axial planes. Spectra were quality-
assessed to ensure appropriate voxel localisation, shim-
ming and water suppression. Raw data were processed
using LCModel [8] to generate quantitative metabolite
concentrations scaled to the water signal.
Comparison was made with MRS metabolite data
from a cohort of children with normal appearing MRI
and similar age profile who had undergone MRI/MRS
for investigation of various suspected neurodegenerative
and neurocognitive conditions (white matter, n = 53,
median (range) age 4.7(0.5-16.7) years; basal ganglia n =
63, 4.1(0.5-16.7) years).
Statistical Analysis
Mean spectra were generated for each cohort for basal
ganglia and white matter from LCModel fitted spectra
after baseline subtraction. Spectra were compared by
qualitative visual inspection.
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Page 2 of 7Table 1 Clinical features of propionic acidaemia cohort and MR Imaging findings
Neonatal
CVVH?
Liver
Transplant
(age, years)
Other diagnoses Age at
MRS
(years)
Status at
time of
MRS
Metabolic Drugs & Dietary
Restrictions
Acute encephalopathic
episodes: complications
MRI findings
Maintenance Acute Basal ganglia Other features
1 Yes 1.5 Stable LC, SB, PR Normal
2 Yes Hypo-throidism 1 Enceph. SP, SB, LC, T,
M, PR
SP, SB, NC Sepsis & hyper-
ammonaemia,
Acutely swelling
caudate, dentate
1.2 Stable SB, LC, T, PR Resolving swelling Delayed myelination, enlarged
ventricles
3 Enceph. SB, LC, T, PR Cardiomyopathy,
pneumonia
Acute swelling
caudate, putamen,
dentate
Delayed myelination, enlarged
ventricles, hippocampal atrophy
3 No Epilepsy 9.5 Enceph. SB, LC, PR SB LC Rhabdomyolysis Cystic
encephalomalacia
Enlarged ventricles/cerebral
volume loss
4 Yes Hypo-thyroidism 4 Stable SB, SP, LC, PR Normal
6 Enceph. SB, SP, LC, PR SP, SB, LC Pneumonia Acute swelling
caudate + putamen
Cerebral volume loss, small
hippocampi
5 Yes 0.6 Stable SB, LC, PR Normal Mild ventricular dilation
6 No 3 Stable SB, SP, LC, PR Normal Hippocampal sclerosis
7 No Yes (1.3) 15 Stable Anti-rejection Normal
8 No Yes (2.5) Myoclonic
epilepsy
13 Stable Anti-rejection
LC
Normal Mild ventricular enlargement.
Unilateral mesial temporal
sclerosis
MRS, magnetic resonance spectroscopy; CVVH, Continuous veno-venous haemofiltration; LC, L-carnitine; SP, Sodium Phenylbutyrate; SB, Sodium Benzoate; M, metronidazole; T, thyroxine; NC, N-Carbamylglutamate;
PR, dietary protein restriction; Enceph., denotes acute encephalopathic episode
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7Metabolite concentrations for each region were com-
pared between groups by Mann Whitney nonparametric
U test (SPSS Statistics 17.0), with the p-value deter-
mined by the exact 2-tailed significance, with signifi-
cance level set at p < 0.05.
Results
Magnetic Resonance Imaging
The basal ganglia appeared normal in all children (n =
6) prior to any severe acute episode beyond the neonatal
period. MRI obtained during severe acute episodes
demonstrated abnormal signal in the basal ganglia vari-
ably including the caudate heads, putamen and globus
pallidi and in some cases there was also evidence of
acute changes in the dentate nuclei and cerebral cortex.
One child demonstrated evidence of previous basal
ganglia infarction relating to a previous acute encephalo-
pathic episode, with cystic degeneration of caudate,
putamen and globus pallidus. Interestingly the hippo-
campi appeared atrophic in seven cases. Cerebral
volume loss was most marked in children with preced-
ing severe acute episodes. The two children who had
liver transplantation had normal appearing basal ganglia,
cortex and white matter on MRI undertaken more than
10 years post-transplant, with one showing probable
temporal mesial sclerosis.
Magnetic Resonance Spectroscopy
Analysis of mean spectra (figure 1) and mean metabolite
concentrations (table 2) demonstrate metabolite altera-
tions in basal ganglia and parieto-occipital white matter,
in particular during severe acute episodes.
MRS studies undertaken during metabolic stability
before any severe acute episodes beyond the neonatal
period demonstrated decreased Glx in basal ganglia
compared to the normal MRI comparator group but a
trend to increase in white matter. Glutamine alone was
significantly decreased in basal ganglia during metabolic
stability. Mean lactate was not elevated, although two
cases had reliably detected lactate in basal ganglia.
There was no significant decrease in the total N-acety-
laspartate and N-acetylaspartylglutamate (tNAA) in this
group.
MRS studies acquired during severe acute episodes
demonstrated significantly decreased tNAA, Glx and
creatine, and significantly elevated lactate, in the basal
ganglia compared to both the normal MRI comparator
group and to the metabolically stable propionic acidae-
mia cohort. In white matter lactate was significantly ele-
vated but other metabolites were not significantly
altered. (Data shown are for all severe acute episodes;
analysis of first severe acute episode only demonstrated
similar findings). There were no significant differences
between groups in brain myo-inositol, and no propionic
acid was detected in the propionic acidaemia cohort.
Separate analysis of brain metabolites from the two
children post-liver transplant demonstrated normal basal
ganglia tNAA and slightly decreased Glx. tNAA was ele-
vated in white matter and total choline decreased.
Discussion
The data presented represent the largest series of chil-
dren with the severe neonatal form of propionic acidae-
mia to be investigated with MRS, and is to our
Figure 1 Mean MR spectra from basal ganglia during metabolic stability and acute encephalopathy in propionic acidaemia.( A )
Metabolically stable and (B) acutely encephalopathic propionic acidaemia patients compared to normal imaging comparator cohort. ppm, parts
per million; a.u., arbitrary units. Major metabolite peaks identified (labelled arrows), significant differences indicated by *. Glx, glutamine +
glutamate; Ins, myo-inositol; Cre, Creatine; NAA, N-acetylaspartate; Lac, lactic acid.
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acute encephalopathic episodes. The selective vulnerabil-
ity of the basal ganglia in PA is well established, and our
data provide further insight in to processes occurring
within the basal ganglia. MRI results found that basal
ganglia appeared normal in children who had not had a
severe acute encephalopathic episode beyond the neona-
tal period, as similarly reported in glutaric aciduria [9],
but were acutely damaged during episodes of acute ill-
ness. Similarly brain metabolite alterations were more
marked during severe acute episodes.
Decreased tNAA is seen in many pathologies, and is
thought to reflect loss of viable neurons [10] including
following acute ischemic stroke [11]. Elevated lactate
suggests a switch to anaerobic respiration, reflecting
local ischaemia or mitochondrial dysfunction. As pre-
viously reported, elevated lactate was seen in two of the
cases during metabolic stability, suggesting that brain
tissue metabolism is not normal even when metabolism
is well controlled.
The alterations seen in glutamine and glutamate in
basal ganglia are of particular note. Glx was significantly
decreased during severe acute episodes, with a smaller
(non-significant) decrease noted in basal ganglia in stu-
dies acquired during metabolic stability. The ratio of
Glx/tNAA was lower in the propionic acidaemia cohort
than in cohorts of children with other defined inherited
metabolic disorders including a cohort with confirmed
respiratory chain disorders, while the Glx/NAA ratio
was elevated in a cohort with the urea cycle disorder
argininosuccinic aciduria (JED, unpublished data). This
suggests that the alterations seen in Glx here were not
simply a reflection of neuronal loss represented by
lower tNAA.
Table 2 Metabolite concentrations in basal ganglia and parieto-occipital white matter
Basal ganglia metabolites (mM, mean (standard deviation))
Propionic Acidaemia Normal MRI
comparator group
Metabolic stability (6 studies
from 6 patients)
Acute encephalopathy (5 studies
from 3 patients)
Post-liver transplant (2 studies
from 2 patients)
(63 studies)
Median age (years,
(range))
3.6 (0.6-15.9) 6.13 (1.0-9.4) 14.4 (12.9-15.9) 4.1 (0.5-16.7)
N-Acetylaspartate 5.03 (0.53) 3.89 (0.20)†# 5.35 (0.28) 5.21 (0.51)
Creatine 4.57 (0.47) 3.71 (0.58)† $ 4.42 (0.14) 4.55 (0.59)
Glutamine 1.29 (0.30) * 1.00 (1.00)* 1.27 (0.25) 1.98 (0.79)
Glutamate 4.28 (0.25) 3.07 (0.60)†# 4.30 (0.39) 4.45 (0.78)
Glutamine
+Glutamate
5.57 (0.41) * 4.07 (1.19)† $ 5.57 (0.28) 6.43 (1.39)
myo-Inositol 2.58 (0.26) 2.79 (0.90) 2.39 (0.0) 2.49 (0.43)
Lactate 0.21 (0.25) 0.93 (0.34)†# 0.00 (0.32) 0.11 (0.20)
Choline 1.10 (0.18) 1.16 (0.29) 0.90 (0.63) 1.11 (0.18)
White matter metabolites (mM, mean (standard deviation))
Propionic Acidaemia Normal MRI
comparator group
Metabolic stability (5 studies
from 5 patients)
Acute encephalopathy (4 studies
from 3 patients)
Post-liver transplant (2 studies
from 2 patients)
(53 studies)
Median age (years,
(range))
3.1 (0.6-15.9) 7.74 (3.0 -9.4) 14.4 (12.9-15.9) 4.7 (0.5-16.7)
N-Acetylaspartate 5.28 (0.80) 4.50 (0.47) 6.11 (0.39) 5.11 (0.73)
Creatine 3.55 (0.19) * 3.33 (0.53) 3.70 (0.00) 3.18 (0.47)
Glutamine 1.43 (0.54) 1.34 (1.30) 1.62 (0.49) 1.32 (0.62)
Glutamate 3.83 (0.45) 2.65 (0.44)*$ 4.27 (0.31) 3.51 (0.78)
Glutamine
+Glutamate
5.26 (0.89) 3.98 (1.54) 5.89 (0.80) 4.84 (1.18)
myo-Inositol 2.73 (0.31) 2.57 (0.39) 2.79 (0.02) 2.57 (0.39)
Lactate 0.40 (0.30) 0.81 (0.74)* 0.32 (0.45) 0.21 (0.28)
Choline 0.93 (0.15)* 1.12 (0.37) 0.83 (0.09) 1.08 (0.15)
Comparison between propionic acidaemia cohorts and normal MRI comparator group.
Mann Whitney U test (2 tailed exact significance) for difference in metabolite concentrations between Normal MRI Comparator group and propionic acidaemia
cohorts,*p < 0.05, † p < 0.01. Mann Whitney U test (2 tailed exact significance) for difference in metabolite concentrations between stable and encephalopathic
propionic acidaemia cohort, $ p < 0.05, # p < 0.01
Davison et al. Orphanet Journal of Rare Diseases 2011, 6:19
http://www.ojrd.com/content/6/1/19
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tamate overlap, there is increasing evidence that they
can be differentiated in the analysis of cohorts even at
1.5Tesla using software such as LCModel. Such evidence
includes Montecarlo simulations of normal brain spectra
fitted with LCModel [12], comparisons of experimental
and simulated basis sets [13], and the finding of a signif-
icant correlation between in vivo and in vitro results for
both glutamate and glutamine detected in brain tumours
[14,15].
A previous MRS study reported elevated basal ganglia
Glx in three metabolically stable propionic acidaemia
patients who had normal ammonia and near-normal
glutamine and glutamate in plasma and cerebrospinal
fluid leading the authors to suggest differential mechan-
isms regulating brain parenchymal metabolism [6].
However this study relied on peak area estimation and
ratio to creatine, whereas the current study provides
more robust quantification. Moreover the reduced gluta-
mine detected by brain MRS is consistent with the
plasma glutamine reduction previously reported in PA
[16], also seen in plasma glutamine levels in our cohort
(data not shown).
The administration of the alternative pathway drugs
used to control hyperammonaemia depletes plasma glu-
tamine and glycine and may contribute to the decreased
brain Glx seen. Furthermore, all children were haemofil-
tered during severe acute episodes which may further
deplete glutamine due to its high sieving coefficient
[17]. However CVVH was instigated after the MRI/MRS
in 80% of cases suggesting that glutamine levels were
already low before CVVH was commenced.
The acute decrease seen in Glx supports the hypothesis
that they are consumed to replenish a depleted Krebs
cycle [4], and that this decrease is a marker of compro-
mised aerobic cellular respiration within brain tissue. It
remains to be determined whether the decreased Glx is
directly detrimental or simply a secondary marker of
compromised metabolic status. Interestingly the decrease
in Glx was greater in the basal ganglia than in white mat-
ter, correlating with the more vulnerable brain region.
There is a need for brain protective strategies during
acute metabolic decompensations, with potential methods
including brain cooling, adequate energy provision, and
anaplerotic therapies. MRS could provide a tool to moni-
tor the effect of dietary supplements aimed at increasing
glutamine levels, specifically monitoring metabolite levels
within the target-organ of interest, namely the brain.
The two children who had liver transplant have had
no severe acute encephalopathic episodes beyond the
neonatal period, and have normal appearing basal gang-
lia on MRI. MRS demonstrated normal/high tNAA
reflecting the absence of major neuronal loss and
correlating with their good neurocognitive status, and
no reliably detected lactate. The small numbers preclude
statistical significance, but Glx was slightly increased in
white matter but decreased in basal ganglia compared to
the comparator group. These results support the
hypothesis that liver transplantation provides systemic
metabolic stability by providing a hepatic pool of func-
tional propionyl CoA carboxylase, thus preventing
further acute metabolic decompensations which are
associated with the risk of brain infarction.
The data presented here have yielded some interesting
observations, however further prospective data collection
and analysis could overcome some of the specific limita-
tions of the present work. In particular, use of higher
field strength MRI scanners (3Tesla and above) would
provide more robust differentiation of the metabolites of
interest, notably glutamine and glutamate. Serial data
collection in specific patients could also confirm the
alterations in brain metabolites seen before, during and
after metabolic decompensations. Finally analysis of a
larger cohort of post-liver transplant patients as well as
longer follow up with serial studies will provide stronger
evidence for the therapeutic value of liver transplanta-
tion in PA.
Conclusions
We have demonstrated that quantitative MRS is able to
offer insight in to in vivo brain metabolic derangements,
and can feasibly be employed in children with acute
encephalopathy. In propionic acidaemia the use of MRS
in conjunction with MRI has confirmed the basal ganglia
as a particularly vulnerable target and has demonstrated
novel insights in to alterations in neurotransmitter meta-
bolites. Evaluation of patients in long-term follow up
after liver transplantation demonstrates the potential for
good neurological outcome and near-normal brain meta-
bolism. MRS provides a tool to directly evaluate the tis-
sue-level effects of novel treatment strategies including
anaplerotic therapies.
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